Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 286

Similar articles for PubMed (Select 14639613)

1.

Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer.

Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, Muti P, Lenner P, Koenig KL, Biessy C, Krogh V, Riboli E, Shore RE, Stattin P, Berrino F, Hallmans G, Toniolo P, Kaaks R.

Int J Cancer. 2004 Jan 10;108(2):262-8.

PMID:
14639613
2.

Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women.

Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E.

J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600.

3.

Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer.

Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, Van Gils CH, Van Noord PA, Rinaldi S, Riboli E, Seidell JC, Grobbee DE, Peeters PH.

Int J Cancer. 2003 Aug 10;106(1):90-5.

PMID:
12794762
4.

Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk.

Oh JC, Wu W, Tortolero-Luna G, Broaddus R, Gershenson DM, Burke TW, Schmandt R, Lu KH.

Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):748-52.

5.

Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.

Stattin P, Bylund A, Rinaldi S, Biessy C, D├ęchaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R.

J Natl Cancer Inst. 2000 Dec 6;92(23):1910-7.

6.

Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a U.S. case-control study.

Lacey JV Jr, Potischman N, Madigan MP, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lurain JR, Fillmore CM, Sherman ME, Brinton LA.

Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):607-12.

7.

A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women.

Lukanova A, Toniolo P, Akhmedkhanov A, Biessy C, Haley NJ, Shore RE, Riboli E, Rinaldi S, Kaaks R.

Int J Cancer. 2001 Jun 15;92(6):888-92.

PMID:
11351312
8.

Serum insulin-like growth factor-I and breast cancer.

Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A.

Int J Cancer. 2000 Dec 1;88(5):828-32.

PMID:
11072255
9.

Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study.

Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S; Japan Public Health Center-based Prospective Study Group.

Int J Cancer. 2007 May 1;120(9):2007-12.

PMID:
17266031
10.

Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.

Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE.

Endocr Relat Cancer. 2006 Jun;13(2):583-92.

11.

Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.

Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D.

Cancer Res. 2003 Jul 15;63(14):3991-4.

12.

Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays.

Rinaldi S, Kaaks R, Zeleniuch-Jacquotte A, Arslan AA, Shore RE, Koenig KL, Dossus L, Riboli E, Stattin P, Lukanova A, Toniolo P.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):48-52.

13.
14.

Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.

Krajcik RA, Borofsky ND, Massardo S, Orentreich N.

Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1566-73.

16.

Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer.

Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak MN, Fuchs CS.

Cancer Res. 2007 Aug 15;67(16):7923-8.

17.

Risk of ovarian cancer in relation to prediagnostic levels of C-peptide, insulin-like growth factor binding proteins-1 and -2 (USA, Sweden, Italy).

Lukanova A, Lundin E, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, Riboli E, Hallmans G, Berrino F, Zeleniuch-Jacquotte A, Toniolo P, Kaaks R.

Cancer Causes Control. 2003 Apr;14(3):285-92.

PMID:
12814208
18.

Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps.

Schoen RE, Weissfeld JL, Kuller LH, Thaete FL, Evans RW, Hayes RB, Rosen CJ.

Gastroenterology. 2005 Aug;129(2):464-75.

PMID:
16083703
19.

Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: a prospective study in northern Sweden.

Palmqvist R, Stattin P, Rinaldi S, Biessy C, Stenling R, Riboli E, Hallmans G, Kaaks R.

Int J Cancer. 2003 Oct 20;107(1):89-93.

PMID:
12925961
20.

Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.

Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X.

J Natl Cancer Inst. 1999 Jan 20;91(2):151-6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk